Yasmin is a birth control pill that contains the active ingredients drospirenone and ethinyl estradiol. It is also known by some people as ocella or syeda. It is used to prevent pregnancy and can help regulate menstrual cycles.
The fiscal range for Yasmin stands at £1.08 to £1.41 per pills. The crux of the pricing revolves around pack dimensions and ingredient quality (21 or 168 mg).
Yasmin contains two active pharmaceutical ingredients: drospirenone and ethinylestradiol. Drospirenone is a synthetic progestogen, and ethinylestradiol is a synthetic estrogen. Drospirenone is derived from spironolactone, which has antimineralocorticoid properties.
Yasmin works by inhibiting ovulation, thickening cervical mucus to impede sperm movement, and altering the endometrium to prevent implantation. The drospirenone component has anti-androgenic effects, which can help reduce acne and seborrhea in users.
Yasmin is primarily prescribed as a contraceptive for preventing pregnancy. Additionally, it is indicated for the treatment of moderate acne in women who opt for oral contraceptives and for the management of premenstrual dysphoric disorder (PMDD).
Yasmin should be taken orally once daily, ideally at the same time each day for optimal efficacy. The pill should be taken with water, with or without food. A typical cycle is 21 active pills followed by 7 inactive pills, during which withdrawal bleeding occurs.
For women starting Yasmin, it is advised to begin on the first day of their menstrual cycle for immediate contraceptive protection. Alternatively, it can start on the first Sunday after the onset of menstruation, employing additional contraception for the first seven days.
If one active tablet is missed, it should be taken as soon as remembered, and the following tablet taken at the regular time. Missing two or more consecutive active tablets requires following specified catch-up protocols and using backup contraception for seven days.
Yasmin can interact with medications such as rifampin, anticonvulsants like phenytoin and carbamazepine, and antimycotics including griseofulvin. These interactions may reduce contraceptive effectiveness, necessitating alternative or additional contraceptive measures.
Yasmin is contraindicated in women with a history of thromboembolic disorders, hepatic dysfunction, known or suspected breast cancer, undiagnosed vaginal bleeding, and pregnancy. It should not be used by individuals with renal insufficiency or adrenal disease.
Common side effects include nausea, vomiting, headache, breast tenderness, and mood changes. Users might also experience changes in menstrual flow such as lighter periods or breakthrough bleeding, particularly in the initial months of use.
Serious side effects associated with Yasmin include venous thromboembolism, arterial thromboembolism, hypertension, and gallbladder disease. Symptoms such as sudden vision loss, severe chest pain, and unilateral limb swelling require immediate medical attention.
Regular blood pressure monitoring is recommended for Yasmin users. Periodic breast exams and Pap smears are also advisable. Liver function and lipid profile assessments may be warranted in prolonged usage.
Yasmin is not recommended for use in women over the age of 35 who smoke due to an increased risk of cardiovascular events. Caution is also advised for women with a history of depression, as hormonal changes could potentially exacerbate symptoms.
Store Yasmin in a cool, dry place at temperatures between 15°C and 30°C (59°F to 86°F). Protect the package from moisture and direct sunlight. Keep it out of reach of children and pets to avoid accidental ingestion.
Each package of Yasmin typically contains 28 tablets: 21 active tablets each containing 3 mg of drospirenone and 0.03 mg of ethinylestradiol, and 7 inactive tablets. Active tablets are usually yellow, whereas inactive tablets are white.
Drospirenone and ethinylestradiol exhibit linear pharmacokinetics over the dosage range. Drospirenone reaches peak plasma concentration in approximately 1-2 hours, while ethinylestradiol in about 2 hours. Both exhibit high plasma protein binding.
Yasmin has no significant long-term impact on bone mineral density. It may be favorable compared to other hormonal contraceptives that can negatively affect bone health, particularly in younger women.
Some users report weight gain during Yasmin use, attributed to fluid retention. Nonetheless, clinical trials show minimal average weight variation, underscoring the need to evaluate the cause of weight changes individually.
Yasmin may cause mood changes, which can range from mild irritability to severe depression. Women with a history of mood disorders should consult their healthcare provider to weigh risks versus benefits.
Studies demonstrate that Yasmin maintains high efficacy over extended periods with consistent use. Long-term users may experience reduced menstrual bleeding and related symptoms like dysmenorrhea (painful periods).
Yasmin is not suitable for use as an emergency contraceptive. Alternative preparations like levonorgestrel or ulipristal should be used for post-coital contraception following unprotected intercourse or contraceptive failure.